S
Steven R. Steinhubl
Researcher at Scripps Health
Publications - 332
Citations - 25961
Steven R. Steinhubl is an academic researcher from Scripps Health. The author has contributed to research in topics: Clopidogrel & Percutaneous coronary intervention. The author has an hindex of 72, co-authored 323 publications receiving 23387 citations. Previous affiliations of Steven R. Steinhubl include Cleveland Clinic & Alaska Native Tribal Health Consortium.
Papers
More filters
Journal ArticleDOI
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Steven R. Steinhubl,Peter B. Berger,J. Tift Mann,Edward T.A. Fry,Augustin DeLago,Charles Wilmer,Eric J. Topol +6 more
TL;DR: Following PCI, long-term clopidogrel therapy significantly reduced the risk of adverse ischemic events and subgroup analyses suggest that longer intervals between the loading dose and PCI may reduce events.
Journal ArticleDOI
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Deepak L. Bhatt,Keith A.A. Fox,Werner Hacke,Peter B. Berger,Henry R. Black,William E. Boden,Patrice Cacoub,Eric A. Cohen,Mark A. Creager,J. Donald Easton,Marcus Flather,Steven M. Haffner,Christian W. Hamm,Graeme J. Hankey,S. Claiborne Johnston,Koon Hou Mak,Jean-Louis Mas,Gilles Montalescot,Thomas A. Pearson,P. Gabriel Steg,Steven R. Steinhubl,Michael A. Weber,Danielle M. Brennan,Liz Fabry-Ribaudo,Joan E. Booth,Eric J. Topol +25 more
TL;DR: In this article, the authors compared the effect of clopidogrel and low-dose aspirin on the rate of myocardial infarction, stroke, or death from cardiovascular causes.
Journal ArticleDOI
Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention
Steven R. Steinhubl,Peter B. Berger,J. Tift,Mann,Edward T.A. Fry,Augustin DeLago,Charles Wilmer,Eric J. Topol +7 more
TL;DR: Long-term clopidogrel therapy significantly reduced the risk of adverse ischemic events following percutaneous coronary intervention and started with a preprocedure loading dose, both in addition to aspirin therapy.
Journal ArticleDOI
Variability in platelet responsiveness to clopidogrel among 544 individuals.
Victor L. Serebruany,Steven R. Steinhubl,Peter B. Berger,Alex I. Malinin,Deepak L. Bhatt,Eric J. Topol +5 more
TL;DR: Clinical trials are needed to define whether hyporesponders to clopidogrel are at increased risk for thrombotic events and whether hyper-responders are at increase risk for bleeding.
Journal ArticleDOI
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
James J. Ferguson,Robert M. Califf,Elliott M. Antman,Marc Cohen,Cindy L. Grines,Shaun G. Goodman,Dean J. Kereiakes,Anatoly Langer,Kenneth W. Mahaffey,Christopher C. Nessel,Paul W. Armstrong,Alvaro Avezum,Phil Aylward,Richard C. Becker,Luigi M. Biasucci,Steven Borzak,Jacques Col,Marty J Frey,Edward T.A. Fry,Dietrich C. Gulba,Sema Güneri,Enrique P. Gurfinkel,Robert A. Harrington,Judith S. Hochman,Neal S. Kleiman,Martin B. Leon,Jose Lopez-Sendon,Carl J. Pepine,Witold Rużyłło,Steven R. Steinhubl,Paul S. Teirstein,Luis Toro-Figueroa,Harvey D. White +32 more
TL;DR: Enoxaparin has demonstrated advantages over unfractionated heparin in patients with non-ST-segment elevation acute coronary syndrome (ACS) treated with a conservative strategy.